scholarly journals Multifaceted Effect of Rubus Occidentalis on Hyperglycemia and Hypercholesterolemia in Mice with Diet-Induced Metabolic Diseases

Nutrients ◽  
2018 ◽  
Vol 10 (12) ◽  
pp. 1846 ◽  
Author(s):  
Jiyeon Kim ◽  
Jinho An ◽  
Heetae Lee ◽  
Kyungjae Kim ◽  
Su Lee ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Metabolic Diseases ◽  
Density Lipoprotein ◽  
Hdl Cholesterol ◽  
Experimental Period ◽  
Tolerance Test ◽  
Metabolic Phenotype ◽  
Simultaneous Occurrence ◽  
Beneficial Effects ◽  
Rubus Occidentalis

Metabolic syndrome is characterized by a combination of several metabolic disorders, including obesity, hyperglycemia, and hyperlipidemia. A simultaneous occurrence is one of the most crucial features of metabolic syndrome; therefore, we selected an animal model in which this would be reflected. We fed C57BL/6N mice a high-fat diet for 23 weeks to develop metabolic syndrome and examined the efficacy of Rubus occidentalis (RO) for hyperglycemia and hypercholesterolemia. Oral administration of RO for 16 weeks improved hyperglycemia as indicated by significantly decreased fasting glucose levels and a glucose tolerance test. Improvements were also observed in hypercholesterolemia, in which significant decreases in serum total cholesterol, non-high-density lipoprotein (non-HDL) cholesterol, apolipoprotein A-1, and apolipoprotein B levels were observed. The time comparison of major biomarkers, observed at the initiation and termination of the experimental period, consistently supported the beneficial effects of RO on each metabolic phenotype. In addition, RO treatment attenuated the excessive fat accumulation in hepatic and adipose tissue by decreasing the size and number of lipid droplets. These results suggested that RO simultaneously exerted antihyperglycemic and antihyperlipidemic effects in mice with diet-induced metabolic syndrome.

scholarly journals Impact of the Level of Adherence to Mediterranean Diet on the Parameters of Metabolic Syndrome: A Systematic Review and Meta-Analysis of Observational Studies

Nutrients ◽  
2021 ◽  
Vol 13 (5) ◽  
pp. 1514
Author(s):  
Dimitra Rafailia Bakaloudi ◽  
Lydia Chrysoula ◽  
Evangelia Kotzakioulafi ◽  
Xenophon Theodoridis ◽  
Michail Chourdakis
Keyword(s):  
Metabolic Syndrome ◽  
Mediterranean Diet ◽  
Observational Studies ◽  
Positive Impact ◽  
Fasting Blood Glucose ◽  
Density Lipoprotein ◽  
Hdl Cholesterol ◽  
Central Registry ◽  
High Adherence ◽  
The Impact

High adherence to the Mediterranean diet (MD) has been associated with a lower prevalence of Metabolic Syndrome (MetS). The present study aimed to investigate the impact of MD adherence on parameters of MetS. A systematic literature search was performed in PubMed, Cochrane Central Registry of Clinical Trials (CENTRAL), Scopus, EMBASE, Web of Science and Google Scholar databases. Observational studies that recorded adherence to MD and components/measures of the MetS, such as waist circumference (WC), blood pressure (BP), fasting blood glucose (FBG), high-density lipoprotein (HDL) cholesterol and triglycerides (TG), were included in this study. A total of 58 studies were included in our study. WC and TG were significantly lower in the high adherence MD group (SMD: −0.20, (95%CI: −0.40, −0.01), SMD: −0.27 (95%CI: −0.27, −0.11), respectively), while HDL cholesterol was significantly higher in the same group (SMD: −0.28 (95%CI: 0.07, 0.50). There was no difference in FBG and SBP among the two groups (SMD: −0.21 (95%CI: −0.54, 0.12) & SMD: −0.15 (95%CI: −0.38, 0.07), respectively). MD may have a positive impact on all parameters of MetS. However, further research is needed in this field.

scholarly journals Fibroblast cholesterol efflux to plasma from metabolic syndrome subjects is not defective despite low high-density lipoprotein cholesterol

2008 ◽  
Vol 158 (1) ◽  
pp. 53-60 ◽  
Author(s):  
Robin P F Dullaart ◽  
Albert K Groen ◽  
Geesje M Dallinga-Thie ◽  
Rindert de Vries ◽  
Wim J Sluiter ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
High Density Lipoprotein ◽  
Cholesterol Efflux ◽  
Density Lipoprotein ◽  
Hdl Cholesterol ◽  
Cholesterol Esterification ◽  
Cellular Cholesterol ◽  
Apo E ◽  
Pltp Activity ◽  
Cellular Cholesterol Efflux

ObjectiveWe tested whether in metabolic syndrome (MetS) subjects the ability of plasma to stimulate cellular cholesterol efflux, an early step in the anti-atherogenic reverse cholesterol transport pathway, is maintained despite low high-density lipoprotein (HDL) cholesterol.DesignIn 76 subjects with and 94 subjects without MetS based on the National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) criteria, we determined plasma (apo)lipoproteins, pre-β-HDL formation, phospholipid transfer protein (PLTP) activity, cholesterol esterification (EST), cholesteryl ester transfer (CET), adiponectin, and the ability of plasma from each subject to stimulate cholesterol efflux out of cultured fibroblasts obtained from a single donor.ResultsApo E, PLTP activity, EST, and CET were higher (P=0.04 to <0.001), whereas adiponectin was lower in MetS subjects (P<0.01). Pre-β-HDL and pre-β-HDL formation were not different between subjects with and without MetS. Cellular cholesterol efflux to plasma from MetS subjects was slightly higher versus plasma from subjects without MetS (8.8±1.0 vs 8.5±0.9%,P=0.05), but the difference was not significant after age, sex, and diabetes adjustment. Cellular cholesterol efflux was positively related to pre-β-HDL formation, EST, PLTP activity, and apo E (P<0.05 for all by multiple linear regression analysis), without an independent association with MetS and diabetes status.ConclusionsThe ability of plasma from MetS subjects to promote fibroblast cholesterol efflux is not defective, although HDL cholesterol is decreased. Higher cholesterol esterification, PLTP activity, and apo E levels may contribute to the maintenance of cholesterol efflux in MetS.

Abstract 110: Vascular Smooth Muscle Sirtuin-1 Protects Against Diet-Induced Aortic Stiffness

Hypertension ◽  
2016 ◽  
Vol 68 (suppl_1) ◽  
Author(s):  
Jessica Fry ◽  
Leona Al Sayah ◽  
Robert Weisbrod ◽  
Isabelle Van Roy ◽  
Xiang Weng ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Smooth Muscle ◽  
Vascular Smooth Muscle ◽  
Tolerance Test ◽  
Sirtuin 1 ◽  
Over Expression ◽  
Beneficial Effects ◽  
Overnight Fasting ◽  
Cellular Stresses

Arterial stiffness (AS), a major cardiovascular risk factor, develops within two months in mice fed a high fat, high sucrose diet (HFHS), serving as a model of human metabolic syndrome, and is associated with functional impairment of vascular smooth muscle (VSM) cells. Sirtuin1 (SirT1) is a NAD + -dependent deacetylase induced in response to cellular stresses. Our goal was to study the effects of VSM SirT1 on AS in the context of diet-induced metabolic syndrome. VSM specific genetic SirT1 over-expression (SMTG) prevented AS induced by HFHS, measured in vivo by pulse wave velocity (PWV) over 8 months. Resveratrol or S17834, two polyphenolic compounds known to activate SirT1, prevented HFHS-induced AS and were mimicked by global SirT1 over-expression (SirBACO), without evident metabolic improvements (HFHS-induced weight gains or response to a glucose tolerance test remained unchanged). Additionally, HFHS-induced PWV increases were reversed by one-week treatment with a specific, small molecule SirT1 activator (SRT1720). Overnight fasting acutely decreased PWV in mice fed HFHS for 8 months, but not in mice lacking SirT1 in VSM (SMKO). These beneficial effects of pharmacological, genetic or fasting-induced SirT1 activation against AS, were associated with a decrease in NFκB activation and VCAM-1 and p47phox protein expressions, in aorta and VSM cells. In conclusion, VSM SirT1 activation decreases AS in the setting of obesity by stimulating anti-inflammatory and anti-oxidant pathways in the aortic wall. SirT1 activators may represent a novel therapeutic approach to prevent AS and associated CV complications in overweight/obese individuals with metabolic syndrome.

scholarly journals Circulating Apolipoprotein L1 is associated with insulin resistance-induced abnormal lipid metabolism

2019 ◽  
Vol 9 (1) ◽  
Author(s):  
Kenji Nishimura ◽  
Taichi Murakami ◽  
Toshihiro Sakurai ◽  
Masashi Miyoshi ◽  
Kiyoe Kurahashi ◽  
...  
Keyword(s):  
Insulin Resistance ◽  
Metabolic Syndrome ◽  
Density Lipoprotein ◽  
Hdl Cholesterol ◽  
Insulin Resistant ◽  
Cell Dysfunction ◽  
Fractionation Analysis ◽  
Abnormal Lipid Metabolism ◽  
Hdl Metabolism ◽  
Relationship Of

Abstract Circulating ApolipoproteinL1 (ApoL1) is a component of pre-β-high-density lipoprotein (HDL), however little is known about the relationship of ApoL1 with cardiometabolic factors. Considering previous studies reporting the correlation of ApoL1 to triglyceride, we have hypothesized that ApoL1 associates with insulin-related metabolism. The current study examined their associations in 126 non-diabetic subjects and 36 patients with type 2 diabetes (T2DM). Non-diabetic subjects demonstrated triglyceride (standardized coefficients [s.c.] = 0.204, p < 0.05), body mass index (s.c. =0.232, p < 0.05) and HDL cholesterol (s.c. = −0.203, p < 0.05) as independent determinant of ApoL1 levels, and the significant elevation of ApoL1 in metabolic syndrome. Lipoprotein fractionation analysis revealed the predominant distribution of ApoL1 in large HDL fraction, and the significant increase of ApoL1 in large LDL fraction in high ApoL1 samples with insulin resistance. In T2DM, ApoL1 was higher in T2DM with metabolic syndrome, however ApoL1 was lower with β cell dysfunction. Insulin significantly promotes ApoL1 synthesis and secretion in HepG2 cells. In conclusion, circulating ApoL1 may be associated with abnormal HDL metabolism in insulin resistant status. This may suggest a regulation of insulin signal on the ApoL1 level, leading to offer a novel insight to the ApoL1 biology.

Comparing the validity of continuous metabolic syndrome risk scores for predicting pediatric metabolic syndrome: the CASPIAN-V study

2019 ◽  
Vol 32 (4) ◽  
pp. 383-389 ◽  
Author(s):  
Mehri Khoshhali ◽  
Ramin Heshmat ◽  
Mohammad Esmaeil Motlagh ◽  
Hasan Ziaodini ◽  
Mahdi Hadian ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Fasting Blood Glucose ◽  
Density Lipoprotein ◽  
Principal Component ◽  
Hdl Cholesterol ◽  
Cross Sectional Study ◽  
Risk Scores ◽  
Cross Sectional ◽  
Z Scores ◽  
Iranian Children

Abstract Background The aim of this study was to compare the validity of various approaches to pediatric continuous metabolic syndrome (cMetS) scores including siMS scores (2 waist/height + fasting blood glucose [FBG]/5.6 + triglycerides [TG]/1.7 + systolic blood pressure [BP]/130 + high-density lipoprotein [HDL]/1.02), Z-scores, principal component analysis (PCA) and confirmatory factor analysis (CFA) for predicting metabolic syndrome (MetS). Methods This nationwide cross-sectional study was conducted on 4200 Iranian children and adolescents aged 7–18 years. The cMetS was computed using data on HDL, cholesterol, TGs, FBG, mean arterial pressure (MAP) and waist circumference (WC). The areas under the receiver operating characteristic curves (AUCs) were used to compare the performances of different cMetS scores. Results Data of 3843 participants (52.4% boys) were available for the current study. The mean (standard deviation [SD]) age was 12.6 (3) and 12.3 (3.1) years for boys and girls, respectively. The differences in AUC values of cMetS scores were significant based on the Delong method. The AUCs (95% confidence interval [CI]) were for Z-scores, 0.94 (0.93, 0.95); first PCA, 0.91 (0.89, 0.93); sum PCA, 0.90 (0.88, 0.92), CFA, 0.79 (0.76, 0.3) and also for siMS scores 1 to 3 as 0.93 (0.91, 0.94), 0.92 (0.90, 0.93), and 0.91 (0.90, 0.93), respectively. Conclusions The results of our study indicated that the validity of all approaches for cMetS scores for predicting MetS was high. Given that the siMS scores are simple and practical, it might be used in clinical and research practice.

scholarly journals Metabolic Syndrome—Role of Dietary Fat Type and Quantity

Nutrients ◽  
2019 ◽  
Vol 11 (7) ◽  
pp. 1438 ◽  
Author(s):  
Peter Clifton
Keyword(s):  
Blood Pressure ◽  
Metabolic Syndrome ◽  
Dietary Fat ◽  
Saturated Fat ◽  
Density Lipoprotein ◽  
Hdl Cholesterol ◽  
Fasting Insulin ◽  
Polyunsaturated Fat ◽  
Monounsaturated Fat ◽  
The Impact

Background: Metabolic syndrome increases the risk of cardiovascular disease (CVD) over and above that related to type 2 diabetes. The optimal diet for the treatment of metabolic syndrome is not clear. Materials and Methods: A review of dietary interventions in volunteers with metabolic syndrome as well as studies examining the impact of dietary fat on the separate components of metabolic syndrome was undertaken using only recent meta-analyses, if available. Results: Most of the data suggest that replacing carbohydrates with any fat, but particularly polyunsaturated fat, will lower triglyceride(TG), increase high density lipoprotein (HDL) cholesterol, and lower blood pressure, but have no effects on fasting glucose in normal volunteers or insulin sensitivity, as assessed by euglycemic hyperinsulinemic clamps. Fasting insulin may be lowered by fat. Monounsaturated fat (MUFA) is preferable to polyunsaturated fat (PUFA) for fasting insulin and glucose lowering. The addition of 3–4 g of N3 fats will lower TG and blood pressure (BP) and reduce the proportion of subjects with metabolic syndrome. Dairy fat (50% saturated fat) is also related to a lower incidence of metabolic syndrome in cohort studies.

scholarly journals Prospective Study of Sex-Specific Adiponectin Changes and Incident Metabolic Syndrome: The ARIRANG Study

2019 ◽  
Vol 8 (5) ◽  
pp. 599
Author(s):  
Ji Hye Huh ◽  
Tae Woong Yoon ◽  
Dae Ryong Kang ◽  
Jang Young Kim
Keyword(s):  
Metabolic Syndrome ◽  
Prospective Study ◽  
Adiponectin Level ◽  
Density Lipoprotein ◽  
Hdl Cholesterol ◽  
Population Based ◽  
Clinical Role ◽  
High Baseline ◽  
The Individual

We investigated whether changes in adiponectin levels over time predict incident metabolic syndrome (MetS) in a population-based prospective study. In total, 1110 subjects were categorized into four groups according to their sex-specific median baseline adiponectin levels and the change in adiponectin levels at follow-up: low baseline adiponectin and decreased adiponectin during follow-up (LB&DF), low baseline adiponectin and increased adiponectin during follow-up (LB&IF), high baseline adiponectin and decreased adiponectin during follow-up (HB&DF), and high baseline adiponectin and increased adiponectin during follow-up (HB&IF). During the median 2.4-year follow-up period, 180 (16.2%) subjects developed MetS. Compared to the LB&DF group, the fully adjusted hazard ratio (95% confidence interval) for incident MS was the lowest in the HB&IF group (0.33, (0.17–0.63)), followed by the HB&DF group (0.58, (0.40–0.84)) and LB&IF group (0.63, (0.41–0.93)). This phenomenon was more prominent in men than in women. Among the individual MetS components, increased adiponectin levels during follow-up were significantly associated with lower risks of incident low high density lipoprotein (HDL) cholesterol and incident high blood pressure. This finding suggests that a change in adiponectin level, as well as the baseline adiponectin level, might have a clinical role in the development of MetS among men.

scholarly journals Fish Oil-Derived Furan Fatty Acid: A New Player in the Regulation of Metabolic Syndrome and Fatty Liver Disease

2021 ◽  
Vol 5 (Supplement_2) ◽  
pp. 1243-1243
Author(s):  
Pascal Rowart ◽  
Sonia Salvatore ◽  
Fei Chang ◽  
Nicholas Khoo ◽  
Francisco Schopfer
Keyword(s):  
Mass Spectrometry ◽  
Metabolic Syndrome ◽  
Fatty Acids ◽  
Glucose Tolerance ◽  
Fatty Liver ◽  
Fish Oil ◽  
Glucose Tolerance Test ◽  
Tolerance Test ◽  
Omega 3 ◽  
Beneficial Effects

Abstract Objectives Obesity and non-alcoholic fatty liver diseases (NAFLD) are multifactorial diseases that affect more than 35% of the world's population. Fish oil (FO) is an important dietary component that provides essential omega-3 fatty acids (Ω-3) effective for hypertriglyceridemia with eicosapentaenoic acid shown to reduce cardiovascular and metabolic syndrome-related events. However, the mechanisms involved in these beneficial activities are still unclear. A metabolomic study of healthy volunteers receiving Lovaza, an omega-3-drug, showed a large increase in plasma and urinary metabolite 3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid (CMPF). Moreover, in the diet-induced obesity (DIO) mouse model, CMPF was protective and reversed steatosis. We identified furan fatty acids (FuFA) present both in FO and Lovaza (0.1–1%) as the sources of CMPF and hypothesised that they were responsible for these beneficial effects. Methods We synthesized one FuFA and confirmed its structure by NMR and mass spectrometry and tested whether it had protective effects in this DIO model (23 weeks, 60 kcal% fat). After 16 weeks of the diet, FuFA (25mg/kg/day) was administered by gavage for the last 7 weeks. A glucose tolerance test was performed at week 4th. Tissues and blood were collected at week 7th after 5h fasting. Mass spectrometry, ELISA, and multiplex analysis were performed on plasma. Liver staining (H&E) was also performed to quantify steatosis and ballooning. Results The glucose tolerance test showed improved glucose clearance in FuFA-treated mice compared to vehicle. The fasting level of insulin and c-peptide 2 were respectively 2.9- and 1.5-fold lower in FuFA- compared to the vehicle-treated mice. Additionally, circulating TNF-α was significantly lower (1.6-fold) in FuFA-treated mice. NAFLD activity scores - hepatocytes ballooning and steatosis - were also significantly decreased in FuFA-treated mice by 1.6- and 1.4-fold, respectively. Finally, an MS-based analysis of plasma showed a significant decrease in cholesterol (1.2-fold) and cholesterol-ester (1.4-fold) levels in FuFA-treated mice. Conclusions In conclusion, the beneficial effects observed in Ω-3 and FO treatment on DIO and NAFLD may be related to the presence of FuFA in these dietary preparations. Funding Sources NIH.

scholarly journals Metabolic Syndrome Risk Associated with Atypical Antipsychotic Medication: A Case Report

2021 ◽  
Vol 11 (1) ◽  
pp. 77-79
Author(s):  
Julaeha Julaeha ◽  
Umi Athiyah ◽  
Josephine P Ayuningtyas ◽  
Verra Yuliana ◽  
Andi Hermansyah
Keyword(s):  
Metabolic Syndrome ◽  
Side Effects ◽  
Atypical Antipsychotic ◽  
Atypical Antipsychotics ◽  
Lifestyle Modification ◽  
Screening Program ◽  
Density Lipoprotein ◽  
Hdl Cholesterol ◽  
Caffeine Intake ◽  
Lipid Abnormalities

People with schizophrenia are vulnerable group suffer from metabolic syndrome events. Atypical antipsychotics associated with weight gain, insulin resistance, and profile lipid abnormalities. The present case was 32-year-old man schizophrenia outpatient had experienced metabolic syndrome side effects. Metabolic syndrome characterized by central obesity, hyperglicemia, hypertriglyceridemia, low High Density Lipoprotein (HDL) cholesterol level, and several months feel an increase in appetite. Metabolic syndrome events might be associated with long-term atypical antipsychotics consuming and tobacco use. As pharmacists, We advised the patient to referral primary healthcare service for managing metabolic syndrome side effects. Pharmacists intervention through education and metabolic syndrome screening program have positive impacts on lifestyle modification such as decreasing number of cigarette consumption and caffeine intake, also increasing physical activity. Keywords: Antipsychotics, Atypical antipsychotic, Metabolic syndrome, Pharmacist, Schizophrenia.

scholarly journals HDL cholesterol efflux capacity and concentration in patients with rheumatoid arthritis: a systematic review and meta-analysis

2020 ◽  
Author(s):  
Binbin Xie ◽  
Jiang He ◽  
Yong Liu ◽  
Ting Liu ◽  
Chaoqun Liu
Keyword(s):  
Rheumatoid Arthritis ◽  
Cholesterol Efflux ◽  
Human Subjects ◽  
Meta Analysis ◽  
Density Lipoprotein ◽  
Hdl Cholesterol ◽  
Cochrane Library ◽  
Future Research ◽  
Cholesterol Efflux Capacity ◽  
Beneficial Effects

Abstract Background: Poor cholesterol efflux capacity (CEC) has been proposed to be an independent risk factor for cardiovascular diseases. However, the current evidences in the literature are inconsistent. This meta-analysis aimed to identify whether CEC is impaired or altered by drug therapy in individuals with rheumatoid arthritis (RA).Methods: The PubMed, Embase, and Cochrane library databases were searched to identify studies on CEC in RA patients. The searches were focused on studies in human subjects that were published before 10 June 2020, without language restrictions. The primary outcomes were CEC and the high-density lipoprotein cholesterol (HDL-C) and C-reactive protein levels (CRP) levels.Results: A total of 11 eligible articles, including 6 observational and 5 intervention studies, were retrieved. The pooled results showed that CEC is not significantly lower in RA patients than in healthy controls (SMD: -0.22, 95% CI: -0.65 to 0.20), whereas the plasma HDL-C level is not significantly (WMD: -3.98, 95% CI: -8.32 to 0.37, I² = 54%, P for heterogeneity = 0.050) but is significantly decreased in the RA patients with moderate body mass index (BMI) (WMD: -5.46, 95% CI: -9.40 to -1.52, I² = 37%, P for heterogeneity = 0.175). Furthermore, in the before-after studies, the CEC of RA patients (SMD: 0.20, 95% CI: 0.03 to 0.38) increased, but the plasma HDL-C level (WMD: 3.26, 95% CI: -0.17 to 6.69) remained at a similar level after anti-rheumatic treatment compared to the baseline. In addition, stratified analysis suggested that the Disease Activity Score for 28 joints could be a potential source of heterogeneity for CEC. The funnel plot was relatively symmetric and did not suggest the presence of publication bias.Conclusion：The current meta-analysis demonstrated that HDL-mediated CEC can be improved by the early control of inflammation and anti-rheumatic treatment in RA patients, which is independent of HDL-C levels. Future research is needed to determine whether therapeutic strategies to enhance CEC in RA patients have beneficial effects for preventing CVD.

Sign in / Sign up

Export Citation Format

Share Document